Aquestive Therapeutics (AQST) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.11

Estimate

-$0.13

Surprise

+16.1%

Revenue (period 2026-09-30)

$7.6M

Score today

5.5/10

Revenue source: xbrl.

Aquestive Therapeutics (AQST) reported a narrower loss than forecast — adjusted EPS of -$0.11 against the -$0.13 estimate (a 16.1% beat on a still-unprofitable quarter).

• Aquestive Therapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-03
• Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $51.040M Est — benzinga, 2026-11-03
• Aquestive Therapeutics Q3 EPS $(0.13) Misses $(0.11) Estimate, Sales $7.557M Miss $11.017M Estimate — benzinga, 2026-11-03

TrendMatrix currently rates AQST Sell at 5.5/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +16.1% surprise compares with a +20.9% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$3.88

Price target

$8.12

Stop

$3.61

Upside to target

+109.3%

Reward-to-risk

8.4:1

Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - Specialty & Generic

Market cap

$487.0M

P/E (fwd)

-6.8

52-week range

$2.93–$6.85

Off 52-week high

43.4%

RSI (14)

33

Volume vs avg

0.95×

Score today

5.5/10